CD36 and leukemia: In vivo APOC2 and CD36 knockdown reduces leukemia burden and engraftment to bone marrow, spleen, and peripheral blood (Zhang et al., 2020); therefore APOC2-CD36 signaling may be an attractive therapeutic target.